Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ostabolin-C injection: Phase II data

Data from an 8-month extension of a 4-month double-blind, placebo-controlled Phase II trial showed Ostabolin-C met the primary

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE